Results 31 to 40 of about 179,498 (360)
Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy
Journal of Hematology & Oncology, 2018 Bcr-Abl inhibitors paved the way of targeted therapy epoch. Imatinib was the first tyrosine kinase inhibitor to be discovered with high specificity for Bcr-Abl protein resulting from t(9, 22)-derived Philadelphia chromosome.
Federico Rossari +2 more
semanticscholar +1 more source
Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation.
Cancer Research, 2019 While the use of ATP-competitive tyrosine kinase inhibitors of oncoprotein BCR-ABL1 has enabled durable responses in patients with chronic myeloid leukemia (CML), issues of drug resistance and residual leukemic stem cells remain.
George M. Burslem +6 more
semanticscholar +1 more source
The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia. [PDF]
PLoS Genetics, 2015 The hallmark of Philadelphia chromosome positive (Ph(+)) leukemia is the BCR/ABL kinase, which is successfully targeted by selective ATP competitors. However, inhibition of BCR/ABL alone is unable to eradicate Ph(+) leukemia.
Anahita Rafiei +8 more
doaj +1 more source
Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia [PDF]
Oncogene, 2002 The fusion of 5' parts of the BCR gene to the ABL gene at the second exon yields several forms of an oncogenic Bcr-Abl oncoprotein observed in several types of Philadelphia chromosome positive leukemia patients. The first exon of the BCR gene is a critical part of this fusion, as the coiled-coil domain at the amino terminal domain of the Bcr protein ...
openaire +2 more sources
Nukleonika, 2017 The paper contains a description of a method for the analysis of the complex alpha spectra generated during the measurement of the activity of filters outside of a vacuum chamber under environmental conditions.
Skubacz Krystian
doaj +1 more source
Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment. [PDF]
PLoS ONE, 2009 BACKGROUND:t(9;22) is a balanced translocation, and the chromosome 22 breakpoints (Philadelphia chromosome--Ph+) determine formation of different fusion genes that are associated with either Ph+ acute lymphatic leukemia (Ph+ ALL) or chronic myeloid ...
Xiaomin Zheng +4 more
doaj +1 more source
Transmission of ultrafine particles through separating systems of dust samplers
Journal of Sustainable Mining, 2018 In underground mines there is a radiation hazard associated with natural radioactive nuclides. The main sources of radiation exposure in Polish mines are short-lived radon decay products, radioactive mine water containing radium and the sediments ...
Krystian Skubacz
doaj +1 more source
USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia
Cell Discovery, 2019 Constitutive activation of tyrosine kinase Bcr-Abl is the leading cause of the development and progression of chronic myeloid leukemia (CML). Currently, the application of tyrosine kinase inhibitors (TKIs) targeting the Bcr-Abl is the primary therapy for
Yuning Liao +9 more
semanticscholar +1 more source
BCR-ABL affects STAT5A and STAT5B differentially. [PDF]
PLoS ONE, 2014 Signal transducers and activators of transcription (STATs) are latent cytoplasmic transcription factors linking extracellular signals to target gene transcription. Hematopoietic cells express two highly conserved STAT5-isoforms (STAT5A/STAT5B), and STAT5
Michael Schaller-Schönitz +9 more
doaj +1 more source
Advanced Functional Materials, EarlyView.We have developed DEX/GM, an all‐natural, personalizable hybrid vaccine designed by coating dendritic cell‐derived exosomes (DEX) onto tumor cell membranes (GM) for sustained prophylaxis against glioblastoma (GBM). ABSTRACT Glioblastoma (GBM), one of the most aggressive and lethal brain tumors, remains incurable with a poor clinical prognosis.
Shanshan Li +6 more
wiley +1 more source